Navigation Links
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Date:6/9/2008

00 persons or less in the U.S. Orphan drug designation by the FDA allows for seven years of market exclusivity following approval of a New Drug Application, as well as reduced regulatory fees and additional regulatory support for research and development initiatives.

Ted Daley, president of Bennu, stated, "Huntington's Disease is a terrible, debilitating disorder with no current cure. Available drugs can only minimize symptoms, such as uncontrollable movements and mood swings. The FDA's decision to grant cysteamine orphan drug designation in Huntington's Disease complements our efforts to develop additional indications for cysteamine. We will be building off of the existing preclinical data that shows cysteamine's safety and potential efficacy to treat HD. We look forward to initiating a Phase II clinical study in HD patients in 2008."

Dr. Christopher M. Starr, Raptor's Chief Executive Officer, stated, "We are delighted that the FDA has granted orphan drug designation for cysteamine in HD. Our team at Raptor is well-versed in developing and gaining regulatory approval of new therapies for orphan drug disorders. We hope to contribute some of this orphan drug expertise and know-how to facilitate Bennu's clinical program for HD."

Through its acquisition by merger of Encode Pharmaceuticals in December 2007, Bennu obtained an exclusive, worldwide license to the intellectual property rights for the development of cysteamine from UC San Diego for the treatment of certain diseases including cystinosis, non-alcoholic steatohepatitis ("NASH") and Huntington's disease.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100% ownership of development stage biotechnology company Raptor Pharmaceutical Inc. ("Raptor Inc."); and its 100% ownership of clinical-stage development company Bennu. Raptor Inc. bioengineers novel drug candidates and drug- targeting platforms derived from the human recep
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Applying a well-known optical phenomenon called thin-film interference, ... demonstrated the ability to "paint" ultra-thin coatings onto ... for making future, flexible electronic devices, creating advanced ... rocket ships and spacecraft with extremely lightweight decorative ... water, it becomes iridescent, revealing a myriad of ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... used to kill nematodes. Nematodes are microscopic parasitic ... soil, water, and inside other plants and animals. ... high volatility or other properties promoting migration through ... contain more than 1,000 plant-parasitic nematodes. With more ...
Breaking Biology Technology:Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Canada, Oct. 14 ProtoKinetix (OTC,Bulletin Board: ... research,development and commercialization of patented anti-aging glycopeptides,(AAGPs(TM)), ... OTC Financial,Network (OTCFN), a division of National ... shareholder awareness campaign., "ProtoKinetix, AAGP(TM) platform ...
... SOMERSET, N.J., Oct. 14 Alfacell Corporation,(Nasdaq: ACEL ... quarter,and fiscal year ended July 31, 2008., The ... or $0.06,per basic and diluted common share, for the ... loss of approximately $2.4 million, or $0.05 per,basic and ...
... and Company,(NYSE: LLY ) announced today that its ... for all outstanding,shares of ImClone Systems Incorporated (Nasdaq: ... in cash. Lilly and ImClone previously announced that they ... ImClone., The Board of Directors of ImClone has ...
Cached Biology Technology:ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 2Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 4Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 5Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 2Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 3Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 4
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
(Date:9/30/2014)... urban and farm runoff in Hawaii is causing tumors ... , The study, published Tuesday in the peer-reviewed open-access ... runoff ends up in algae that the turtles eat, ... flippers and internal organs. , Scientists at Duke University, ... Atmospheric Administration (NOAA) conducted the study to better understand ...
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... A new study led by scientists at the ... and Policy and the Rosenstiel School of Marine and ... respond to stress from catch-and-release fishing. The results revealed ... sharks were by far the most vulnerable to fighting ...
... study published in Cell by the teams ... in Biomedicine (IRB Barcelona) and the Institute of Molecular ... at the University of Wageningen, in the Netherlands, unravels ... activate multiple vital plant functions through various gene transcription ...
... say they have opened the window on the natural process of ... could be used to advance therapies for bone fractures and disease. ... the Feb. 13 issue of the journal Cell Reports , ... to allow adult zebra fish to perfectly replace bones lost upon ...
Cached Biology News:New study examines the effects of catch-and-release fishing on sharks 2Scientists unveil a molecular mechanism that controls plant growth and development 2Zebra fish fins help Oregon researchers gain insight into bone regeneration 2
... Certify products ATP-Free using Mo Bio ... sensitive ATP-Free certification service that will allow you ... level of accuracy and enable you to deliver ... Mo Bios ATP detection limit is 3.5 ...
... Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, Canada) ... have collaborated to develop a fluorescence reader ... The DNAscope AT is based on BPIs ... automatically reads up to six ArrayTubes in ...
... a comprehensive kinase analysis service utilizing ... peptide microarrays synthesized on Paraflo microfluidic ... quantitative measurement of kinase kinetic activities, ... service includes preparation of your kinase ...
... The JNK (c-Jun NH2-terminal kinase) ... three identified MAP kinase pathways in ... response to environmental stress, is associated ... itself, and is implicated in the ...
Biology Products: